Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Piracetam→

Piracetam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7491-74-9
Molecular formula
C6H10N2O2
Molecular weight
142.16 g/mol
Drug class
Racetam nootropiccyclic GABA derivative and neuromodulator
Mechanism of action
The mechanism is not fully established. Piracetam modulates neuronal membrane fluidity and membrane-associated signalling and can influence neurotransmission and synaptic plasticity. It does not act as a conventional GABA receptor agonist despite its structural relationship to GABA.
Indications / reported uses
  • Treatment of cortical myoclonus in adults, as an adjunct to other anti-myoclonic therapies, under the UK product label.

Sources: https://www.medicines.org.uk/emc/product/101131/smpc · https://www.ncbi.nlm.nih.gov/books/NBK551680/ · https://www.ema.europa.eu/en/documents/referral/piracetam-article-31-referral-annex-i_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Piracetam Environmental Risk Assessment (ERA) (the Piracetam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.